Daewoong Pharmaceutical069620.KS

About Daewoong Pharmaceutical

Daewoong Pharmaceutical is a major Korean drugmaker whose portfolio spans prescription medicines, internally discovered therapies, and an aesthetics franchise. The company developed the botulinum toxin Nabota, marketed in the United States as Jeuveau through its partner Evolus, and has commercialized drugs of its own discovery, including a treatment for gastroesophageal reflux and a diabetes therapy in the SGLT-2 class. Alongside novel products it sells generics and long-established brands and provides contract manufacturing. Daewoong Pharmaceutical is the main operating subsidiary of Daewoong Co., the group's listed holding company, with the founding Yoon family at the top.

The aesthetics business gives Daewoong a distinctive export profile: toxin sales into the United States run through a single commercial partner, so that relationship, and the litigation-prone, crowded nature of the global toxin market, is a structural watch point. The company's history includes a lengthy trade-secret dispute with a domestic rival over toxin strains, illustrating the legal sensitivities of the category. Domestic prescription revenue faces Korea's periodic reimbursement price cuts. A listed holding company above adds two-tier considerations, while royalty and milestone income from overseas licensing gives earnings a variable component.

Daewoong's lineage reaches back to 1945, and the modern company took shape after Yoon Young-hwan acquired the business in the 1960s, renaming it Daewoong and building national brands around products such as the liver remedy Urusa. In 2002 the group adopted a holding structure, spinning today's listed Daewoong Pharmaceutical out from the parent that became Daewoong Co. The company's defining recent chapter has been aesthetics: its botulinum toxin Nabota, launched domestically in 2014, won U.S. approval in 2019 under the Jeuveau name. Internally discovered drugs for reflux disease and diabetes reached the Korean market in the early 2020s.

Daewoong assembles revenue from complementary layers: high-volume prescription drugs and familiar consumer brands provide the domestic base, contract manufacturing fills plant capacity, and the toxin franchise supplies export growth through a partner-driven model in which Evolus handles U.S. marketing while Daewoong earns through product supply and related payments. Its novel reflux and diabetes medicines follow a regional licensing playbook, with rights sold market by market across Asia and Latin America to partners who shoulder local commercialization, spreading geographic reach without foreign sales infrastructure. At home it competes with Yuhan, GC, and HK inno.N across overlapping therapeutic categories.

Company profile by LineVest editorial. Journalism, not investment advice. Commission a full DART-based report on Daewoong Pharmaceutical →